

Professor of Interventional Cardiology, Houston Methodist IPO Methodist DeBakey Heart Center

Printed as of 4/26/2024

### **Disclosures**

#### Personal Commercial (5)

| Company Name          | Relationship Category                             | hip Category Compensation Level                   |                                     |
|-----------------------|---|---|-------------------------------------|
| Self                  |   |   |                                     |
| Abbott Laboratories   | Research/Research Grants                          | Research/Research Grants Significant (>= \$5,000) |                                     |
| Boston Scientific     | Research/Research Grants Significant (>= \$5,000) |   | Invasive CV Angio and Interventions |
| Edwards Life Sciences | Research/Research Grants                          | Research/Research Grants None (\$0)               |                                     |
| Eli Lilly Inc         | Consultant Fees/Honoraria                         | Modest (< \$5,000)                                | Invasive CV Angio and Interventions |
| Medtronic             | Consultant Fees/Honoraria                         | Significant (>= \$5,000)                          | Invasive CV Angio and Interventions |

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category     | Compensation Level | Topic Area(s)                       |
|---------------------------|---------------------------|--------------------|-------------------------------------|
| Self                      |                           |                    |                                     |
| Siemens<br>† Siemens      | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |

## Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (1)

| Funding Source | Institutional Compensation Level |
|----------------|----------------------------------|
| Siemens        | None (\$0)                       |

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

### **Agreement**

## Certified Education Attestation | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

## Confidentiality, Disclosure and Assignment Agreement | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/17/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 1/19/2024

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.